


Proposed USPTO Fee Changes Will Make It Much More Expensive to Patent and to Challenge Patents on Therapeutics. You Have an Opportunity to Comment...



The United States Patent & Trademark Office (USPTO or PTO) recently announced [**proposed changes**](#) to certain fees it charges with respect to patent applications, design patents, and America Invents Act (AIA) trials. These changes may significantly increase costs associated with building a robust patent portfolio for New Chemical Entities (NCEs) and Biologics, and to challenge patents at the PTAB. An oral hearing on the proposed changes will be held on **May 18, 2023**, and the USPTO is accepting written comments until **May 25, 2023**.

Read the client alert [**here**](#).